Finnish new technology focused magazine T&T (Tekniikka ja Talous) reports on Maculaser’s goals and timeline in developing novel treatments for […]
Maculaser’s retinal treatment technology exhibited in Media Read more ›
We are excited to announce that Kirsty Happonen joins the Maculaser team as Head of Regulatory Affairs and Quality Assurance. Kirsty
New Head of Regulatory Affairs and Quality Assurance joins the team Read more ›
We are seeking talented professionals to advance our mission of preventing blindness
General Application Read more ›
The paper discusses a new heat treatment for the retina that uses a special method, based on the bioelectrical response
A preclinical study validates the treatment mechanism and feasibility Read more ›
Maculaser has been awarded a 400kEUR Deep Tech Accelerator grant from Business Finland. This brings our total private and public funding
Maculaser awarded Deep Tech Accelerator grant funding Read more ›
Explore the Frontier of AMD Treatment Research: Mooud Amirkavei’s dissertation at Aalto University School of Science, defended on 2023-05-26, offers
Dissertation sheds light on the effects of hormetic heat on AMD Read more ›
Maculaser, a company developing treatments for retinal disorders that affect millions of people worldwide and that currently have no effective
Maculaser receives Instrumentarium Science Foundation grant Read more ›
Maculaser’s novel temperature-controlled subthreshold laser therapy and method for treating diabetic macular edemas is currently being presented at the world’s leading
Maculaser showcased in PhotonicsWest BIOS Read more ›
Maculaser’s Chief Scientific Officer Teemu Turunen presented the results of our clinical usability trial in Visionarium XX, an acknowledged conference
Maculaser in Visionarium XX, conference for wide-scope vision research Read more ›
